- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Rhythm Pharmaceuticals Inc (RYTM)
Assess today's live Rhythm Pharmaceuticals Inc (RYTM) share price, performance and insights using our live NASDAQ: RYTM stock exchange data.
Analyse the historical data and Rhythm Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Rhythm Pharma share price buy/sell indicators using real-time data (or discuss the Rhythm Pharma (RYTM) stock price today with other investors in the Rhythm Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ RYTM share price (ISIN: US76243J1051) to enhance your trading decisions with our free investment tools and resources.
What Is the Rhythm Pharmaceuticals Inc Share Price Today?
The Rhythm Pharma share price today is 87.84.
What Is the Stock Symbol for Rhythm Pharmaceuticals Inc
The stock symbol (or 'ticker') for Rhythm Pharmaceuticals Inc is "RYTM."
What Stock Exchange Does Rhythm Pharmaceuticals Inc Trade On?
Rhythm Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Rhythm Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Rhythm Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Rhythm Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Rhythm Pharma share price buy/sell indicators using real-time data (or discuss the Rhythm Pharma (RYTM) stock price today with other investors in the Rhythm Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ RYTM share price (ISIN: US76243J1051) to enhance your trading decisions with our free investment tools and resources.
What Is the Rhythm Pharmaceuticals Inc Share Price Today?
The Rhythm Pharma share price today is 87.84.
What Is the Stock Symbol for Rhythm Pharmaceuticals Inc
The stock symbol (or 'ticker') for Rhythm Pharmaceuticals Inc is "RYTM."
What Stock Exchange Does Rhythm Pharmaceuticals Inc Trade On?
Rhythm Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Rhythm Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Rhythm Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
87.75
90.90
52 wk Range
58.71
122.20
RYTM is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
87.7590.90
52 wk Range
58.71122.20
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RYTM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
138.20
Upside
+57.33%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings downwards for the upcoming period
- Rhythm Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Rhythm Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Rhythm Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Rhythm Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Rhythm Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
15 Buy
1 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 138.20
(+57.33% Upside)
Rhythm Pharmaceuticals Inc Earnings Call Summary for Q1/2026
- Q1 2026 revenue hit $60.1M, beating forecasts by 8% with EPS at -$0.83; stock surged 8.28% premarket to $92.67
- International sales jumped 27% sequentially, led by Germany and France; IMCIVREE drove 5% quarterly revenue growth
- Company reaffirmed 2026 guidance with non-GAAP operating expenses projected between $385M-$415M
- CEO Meeker highlighted strong HO treatment launch and continued pipeline advancement across multiple indications
- R&D expenses rose 12.7% YoY; strategic investments target geographic expansion despite potential regulatory and competitive risks
Last Updated: 05/05/2026, 14:06
Read Full TranscriptEarnings
Latest Release
05/05/2026
EPS / Forecast
-0.83 / -0.83
Revenue / Forecast
60.11M / 55.62M
Compare RYTM to Peers and Sector
Metrics to compare | RYTM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRYTMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −29.0x | −2.2x | −0.5x | |
PEG Ratio | 2.64 | −0.07 | 0.00 | |
Price/Book | 49.0x | 3.3x | 2.6x | |
Price / LTM Sales | 27.7x | 26.7x | 3.1x | |
Upside (Analyst Target) | 56.7% | 112.9% | 53.0% | |
Fair Value Upside | Unlock | 9.7% | 6.3% | Unlock |
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Rhythm Pharma (NASDAQ: RYTM) Share Price Today?
The Rhythm Pharma stock price today is 87.84 USD.
What Stock Exchange Does Rhythm Pharma (RYTM) Trade On?
Rhythm Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Rhythm Pharma?
The stock symbol (also called a 'ticker') for Rhythm Pharma is "RYTM."
What Is the Current Rhythm Pharma Market Capitalisation?
As of today, Rhythm Pharma (NASDAQ: RYTM) market cap is 6.02B USD.
What Is Rhythm Pharma's (RYTM) Earnings Per Share (TTM)?
The Rhythm Pharma EPS is currently -3.14 (Trailing Twelve Months).
When Is the Next Rhythm Pharma Earnings Date?
Rhythm Pharma's next earnings report will be released on 04/08/2026.
Is RYTM a Buy or Sell From a Technical Analyst Perspective?
Based on today's Rhythm Pharma moving averages and other technical indicators, the daily buy/sell signal for RYTM stock is Neutral.
How Many Times Has Rhythm Pharma Stock Split?
Rhythm Pharma has split 0 times. (See the RYTM stock split history page for full effective split date and price information.)
How Many Employees Does Rhythm Pharma Have?
Rhythm Pharma has 414 employees, based on their latest Companies House report.
What is the current trading status of Rhythm Pharma (NASDAQ: RYTM)?
As of 23/05/2026, Rhythm Pharma (RYTM) is trading at a share price of 87.84 USD, with a previous close of 90.19 USD. The stock has fluctuated within a day range of 87.75 USD to 90.90 USD, while its 52-week range spans from 58.71 USD to 122.20 USD.
What Is Rhythm Pharma (RYTM) Price Target According to Analysts?
The average 12-month price target for Rhythm Pharma is 138.20 USD, with a high estimate of 159 USD and a low estimate of 105 USD. 15 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +57.33% Upside potential.
What Is the RYTM Premarket Price?
RYTM's last pre-market stock price is 90.29 USD. The pre-market share volume is 4,280.00, and the stock has decreased by 0.10, or 0.11%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.